Style | Citing Format |
---|---|
MLA | Ebrahimi M, et al.. "Myositis Autoantibodies in Iranian Myositis Patients: Assessment the Frequency and Clinical Relevancy." Clinical Rheumatology, vol. 41, no. 2, 2022, pp. 533-539. |
APA | Ebrahimi M, Rostamian A, Rafieilatianee R, Najafizadeh SR, Movaseghi S, Faezi ST, Ghazanfari T (2022). Myositis Autoantibodies in Iranian Myositis Patients: Assessment the Frequency and Clinical Relevancy. Clinical Rheumatology, 41(2), 533-539. |
Chicago | Ebrahimi M, Rostamian A, Rafieilatianee R, Najafizadeh SR, Movaseghi S, Faezi ST, Ghazanfari T. "Myositis Autoantibodies in Iranian Myositis Patients: Assessment the Frequency and Clinical Relevancy." Clinical Rheumatology 41, no. 2 (2022): 533-539. |
Harvard | Ebrahimi M et al. (2022) 'Myositis Autoantibodies in Iranian Myositis Patients: Assessment the Frequency and Clinical Relevancy', Clinical Rheumatology, 41(2), pp. 533-539. |
Vancouver | Ebrahimi M, Rostamian A, Rafieilatianee R, Najafizadeh SR, Movaseghi S, Faezi ST, et al.. Myositis Autoantibodies in Iranian Myositis Patients: Assessment the Frequency and Clinical Relevancy. Clinical Rheumatology. 2022;41(2):533-539. |
BibTex | @article{ author = {Ebrahimi M and Rostamian A and Rafieilatianee R and Najafizadeh SR and Movaseghi S and Faezi ST and Ghazanfari T}, title = {Myositis Autoantibodies in Iranian Myositis Patients: Assessment the Frequency and Clinical Relevancy}, journal = {Clinical Rheumatology}, volume = {41}, number = {2}, pages = {533-539}, year = {2022} } |
RIS | TY - JOUR AU - Ebrahimi M AU - Rostamian A AU - Rafieilatianee R AU - Najafizadeh SR AU - Movaseghi S AU - Faezi ST AU - Ghazanfari T TI - Myositis Autoantibodies in Iranian Myositis Patients: Assessment the Frequency and Clinical Relevancy JO - Clinical Rheumatology VL - 41 IS - 2 SP - 533 EP - 539 PY - 2022 ER - |